India's NIFTY Pharma Index received a boost from the new budget package

NFTRegretter · 2026-02-09T05:17:04+00:00

The NIFTY Pharma index has shown positive movement following India's announcement of a substantial budget initiative. The government plans to allocate 100 billion rupees over five years to support the biopharmaceutical sector, enhancing innovation and competitiveness. This has led to a 0.9% rise in the index, reflecting investor optimism and expectations for increased R&D activities and production capacity in the industry.

NFTRegretter

2026-02-09 05:17:04

Abstract generation in progress

The NIFTY Pharma index showed positive momentum following the announcement of a generous budget initiative. According to Jin10, recently there has been increased attention to India’s pharmaceutical sector, driven by significant government funding.

Biopharmaceutical Sector to Receive 100 Billion Rupees for Development

India’s central authorities have allocated 100 billion rupees to support the biopharmaceutical industry over the next five years. This ambitious plan aims to stimulate innovative activities and enhance the competitiveness of domestic companies in the international market. Such investment focus indicates the strategic importance India places on this industry.

Positive Market Reaction and Expectations for Capital Mobilization

The NIFTY Pharma index rose by 0.9%, reflecting investor optimism about the sector’s prospects. Analysts expect that these government guarantees will encourage pharmaceutical companies to accelerate R&D projects and expand manufacturing capacities. The fund index and its components are positioned as the main beneficiaries of this budget policy, which will contribute to the long-term recovery of asset values in this segment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.